02:42 PM EDT, 10/06/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) shares were down 1.7% in recent trading on Monday after the company said its Q3 financial results would take a charge of around $83 million on a pre-tax basis, which is expected to negatively impact its net income by $0.68 per diluted share.
The acquired in-process research and development charge is related to the $80 million upfront payment it made to Hansoh Pharmaceuticals under a 2025 license agreement, Regeneron said in a regulatory filing.
Regeneron's license agreement with Hansoh to acquire development and commercial rights outside of mainland China, Hong Kong, and Macau for HS-20094, a dual GLP-1/GIP receptor agonist in phase 3 clinical development, became effective in July, according to an earlier statement.
Price: 589.44, Change: -10.57, Percent Change: -1.76